Cure Pharmaceuticals will pay $20 million in cash and stock upfront, with an additional $4 million in working capital that will focus on fueling growth.
The partnership will offer data via the Lotame Data Exchange, providing mainstream marketers with previously hard-to-find CBD audience data for data enrichment, targeting and analytics.
The combination will add Tech-Holdings’ The Gold Q and AntiDos brands to Vertical Wellness' portfolio and enable it to offer proprietary products to its partners, the companies said.